Nectin Therapeutics
Nectin Therapeutics
Biotech company developing next-generation immunotherapy agents to unlock the immune system.
About
Nectin Therapeutics develops immuno-oncology and ADC breakthrough therapies to overcome tumor escape and resistance mechanisms. Their diverse pipeline includes novel immuno-oncology antibodies and ADCs, with an anti-PVR asset currently in Phase 1 clinical trials. They aim to address difficult-to-treat cancers for patients who do not respond to approved immuno-oncology therapies.
Key facts
- Website
- nectintx.com
- Founded
- 2016
- Employees
- 11
- Total funding
- $64M (Series C)
- Valuation
- Private
- Business model
- B2B
- Tags
- Life SciencesImmunotherapyImmunologyCancerCancer Immunotherapy
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 6 May 2024 | Series C | $10M | Guangzhou-Israel Biotechnology Fund (GIBF) |
| 28 Feb 2024 | Grant | $3M | EU EIC Accelerator |
| 30 Nov 2022 | Series B | $25M | Peregrine Ventures, Israel Biotech Fund |
| 9 Mar 2022 | Series A | $5M | Cancer Focus Fund |
| 1 May 2021 | Series A | $15M | - |
| 20 Jul 2020 | Seed | $6M | - |
Tech stack
Detected on nectintx.com, last scanned 30 Jul 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Analytics 4, Segment
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Microsoft 365
Add first review
Frequently asked
How much funding has Nectin Therapeutics raised?
Nectin Therapeutics has raised a total of $64M in funding. The most recent round on record is Series C.
How many employees does Nectin Therapeutics have?
Nectin Therapeutics has approximately 11 people on record.